Tiziana life sciences ltd. receives nasdaq deficiency notice

New york, july 21, 2023 (globe newswire) -- tiziana life sciences (nasdaq: tlsa) ("tiziana" or the "company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “notice”) on july 19, 2023 from the nasdaq stock market llc (“nasdaq”) that the company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the company's common shares on the nasdaq capital market, as set forth in nasdaq listing rule 5450(a)(1) (the “minimum bid price requirement”). the notice indicated that, consistent with nasdaq listing rule 5810(c)(3)(a), the company has 180 days, or until january 16, 2024 (the “compliance deadline”), to regain compliance with the minimum bid price requirement by having the closing bid price of the company's ordinary share's meet or exceed $1.00 per ordinary share for at least ten consecutive business days.
TLSA Ratings Summary
TLSA Quant Ranking